metricas
covid
Buscar en
Annals of Hepatology
Toda la web
Inicio Annals of Hepatology Association between elevated aminotransferase levels and the metabolic syndrome ...
Información de la revista
Vol. 9. Núm. 2.
Páginas 161-165 (abril - junio 2010)
Compartir
Compartir
Descargar PDF
Más opciones de artículo
Visitas
1216
Vol. 9. Núm. 2.
Páginas 161-165 (abril - junio 2010)
Open Access
Association between elevated aminotransferase levels and the metabolic syndrome in Northern Turkey
Visitas
1216
Beytullah Yildirim
,
Autor para correspondencia
beytullahy@yahoo.com

Correspondence and reprint reques:
, Fikret Ozugurlu, Semsettin Sahin, Huseyin Ozyurt, Omer Atis, Ali Akbas, Yeliz Akturk, Metin Ozdemir§, Idris Sahin||, Yunus Bulut§, Ilker Etikan, M.Murat Firat
* Department of Gastroenterology
Department of Biochemistry
Department of Radiology
§ Department of Microbiology
Department of Biostatistics, Gaziosmanpasa University School of Medicine, Tokat, Turkey
|| Department of Nephrology, Inonu University School of Medicine, Malatya, Turkey
Este artículo ha recibido

Under a Creative Commons license
Información del artículo
Resumen
Texto completo
Bibliografía
Descargar PDF
Estadísticas
Figuras (1)
Tablas (5)
Table 1. Demographic characteristics of individuals with elevated aminotransferase levels (ALT and / or AST).
Table 2. The p values of comparisons between normal and elevated aminotransferase levels in all participants, male and female.
Table 3. The distributions of the criteria for MetS in individuals with elevated aminotransferase levels without hepatitis (132 persons).
Table 4. The comparisons of participants with elevated aminotransferase levels according to metabolic syndrome.
Table 5. The distributions of risk factors for metabolic syndrome in men with elevated aminotransferase levels.
Mostrar másMostrar menos
Abstract

Introduction. Elevated aminotransferase levels(ATLs) are alert the physicians for liver-affecting disease and may reflect liver injury. We aimed to determine the prevalence of elevated ATLs and the association of elevated ATLs with the metabolic syndrome(MetS) in a northern province of Turkey.

Materials and methods. Elevated ATLs were evaluated among 1,095 individuals of the Tokat Prevalence Study which have been described in detail elsewhere. 1,095 participants had been selected by a simple random sampling method among 530,000 inhabitants in 70 (12 urban and 58 rural) areas in the province of Tokat which is located in the Black Sea Region of Turkey.

Results. The prevalence of elevated serum ALT, AST, and ALT and/ or AST were found as 11%, 7.2%, and 13.3%, respectively. Increased BMI, fatty liver, and MetS were higher in our general population with elevated ATLs. After exclusion of individuals with hepatitis B or hepatitis C infection, 132 individuals with elevated ATLs (91 male and 41 female) were evaluated. MetS was found in 59 participants and its prevalence was markedly higher in females with elevated ATLs (p < 0.0001). When the males with elevated ATLs were evaluated, the ALT levels of the persons who have no risk of MetS (p = 0.007) and the persons who have one risk of MetS (p = 0.001) were lower than the persons with MetS.

Conclusions. Elevated ATLs are common and it’s an important cause is MetS in Northern Turkey.

Key words:
Elevated aminotransferase levels
Metabolic syndrome
Risk factors
Turkey
Texto completo
Introduction

Elevated aminotransferase levels (ATLs) are alert the physicians for liver-affecting disease and may reflect liver injury. The alanine aminotransferase (ALT) levels are more specific indicators of liver injury than aspartate aminotransferase (AST) levels.1 Some factors like chronic hepatitis, fatty liver, cho-lelithiasis, hyperglycemia, hyperlipidemia, obesity, medications, alcohol consumption, hemochromato-sis, Wilson’s disease, and alphal-antitrypsin deficiency may affect ATLs.1-3 Moreover, some previous studies shown that the prevalence of elevated liver enzymes is higher in individuals with metabolic syndrome (MetS).4,5

The causes of elevated ATLs may change according to ethnicity, geographic region, and develop situation of countries. If these causes (which effect liver enzymes) are known, the most of all factors may be forecast. Thus, the etiologic factor should be determined with low cost and less time.

To date, no study has assessed the relationship of elevated ATLs and the MetS in a population-based study of Turkey. In this study, we aimed to determine:

  • 1.

    The prevalence of elevated aminotransferase levels.

  • 2.

    The association of elevated aminotransferase levels with the metabolic syndrome in urban and rural population in a northern province of Turkey.

Materials and Methods

The individuals of Tokat Prevalence Study, have been described in detail elsewhere,6,7 were evaluated in this study. Briefly, one thousand and ninety five participants had been selected by a simple random sampling method among 530,000 inhabitants in 70 (12 urban and 58 rural) areas in the province of Tokat which is located in the Black Sea Region of Turkey.

All subjects gave informed consent and the study protocol was approved by The Ethics Committee of Gaziosmanpasa University. These individuals were interviewed face to face by an internist and a radiologist. Demographic data were obtained, upper abdomen ultrasonographies were done, weight, height, and waist and hip circumference were measured, and blood samples were drawn for each subject. Waist circumference was measured at the mid-point between the lower border of the rib cage and the iliac crest, whereas hip circumference was similarly obtained at the widest point between the hip and buttock, waist-to-hip ratio was calculated. Fatty liver was diagnosed by ultrasonographic findings of liver-kidney contrast, vascular blurring, and deep atte-nuation.8 Systolic and diastolic blood pressure was measured twice on the right arm with a sphygmoma-nometer (Erka, Germany) and the mean of both measurements used for the analyses.

BMI (kg/m2) was calculated as weight divided by the square of height. Subjects with BMI ≥ 25 kg/m2 were classified as overweight. Physical activity was categorized as scarce, mild, intensive, and competitive. Ethanol intake was assessed by a validated questionnaire and expressed as weekly (g/wk) consumption. The cut-off value listed by the test manufacturer for ALT and AST were 55 U/L and 37 U/L, respectively.

MetS, define according to the Adult Treatment Panel III of the National Cholesterol Education Program, was the identification of 3 of the following 5 risk factors: abdominal obesity (>102 cm in male and >88 cm in female), elevated triglycerides (≥ 150 mg/dL), decreased HDL levels (< 40 mg/dL in male and < 50 mg/dL in female), elevated blood pressure (> 130/85), and elevated fasting plasma glucose levels (>110 mg/dL).

Statistical Analysis: Data are expressed as the mean ± SD. Statistical comparison was done by using the Chi-Square and Independent Samples Test or Mann-Whitney U Test according to distributions or numbers of values. Values of p less than 0.05 were evaluated as statistically significant.

Results

The prevalence of elevated serum ALT, AST, and ALT and/or AST were found as 117 (120 indivi-duals), 7.27 (79 individuals), and 13.37 (146 of 1095 individuals), respectively. The mean age of 146 persons were 41.7 ± 16.1 years (range, 18-86) and the rate of male/female was 97/49 (66.4/33.6 percent). In the participants with elevated ATLs, the mean of elevated serum alanine aminotransferase levels in males and in females were 68.7 ± 22.0 U/L and 67.4 ± 31.2 U/L, respectively and statistically significance was not found between gender (p = 0.8). The prevalence of elevated ATLs was higher in males than females (p < 0.0001).

There have a history for drug using in 27 persons (18.57), for smoking in 50 persons (34.27), for alcohol intake (≥ 40 g/wk of ethanol) in 4 persons (2.77), HBs Ag positivity in 8 persons (5.57), and Anti-HCV positivity in 6 persons (4.17). Grade 1, grade 2, and grade 3 steatosis were detected in 25 (17.17), 14 (9.67), and 1 (0.77) individuals of the 146 participants, respectively. The distributions of factors associated with elevated ATLs are shown in table 1. All individuals have a history of at least one risk factor.

Table 1.

Demographic characteristics of individuals with elevated aminotransferase levels (ALT and / or AST).

 
Sex male/female  97/49 
Residence rural/urban  77/69 
Drug usin no/yes  119/27 
Smoker no/yes  96/50 
Body mass index (kg/m2) normal/elevated  39/107 
Diabetes mellitus no/yes  124/22 
Fatty liver no/yes  106/40 
Cholelithiasis no/yes  136/10 
Hypercholesterolemia no/yes  115/31 
Hypertriglyceridemia   
no/yes  71/75 
Alcohol intake Abstainers  126 
< 40 g/wk of ethanol  16 
≥ 40 g/wk of ethanol 
Hepatitis markers HBs Ag and/or Anti-HCV positivity  14 

After exclusion of individuals with hepatitis B or hepatitis C infection, 132 individuals with elevated ATLs (91 male and 41 female) were evaluated (Tables 2 and 3). MetS was found in 59 participants (44.7%) (31 of 91 males, 34.1%; 28 of 41 females, 68.3%) of these individuals and its prevalence was markedly higher in females with elevated ATLs (p < 0.0001). Moreover, the prevalence of MetS in the individuals with elevated ATLs were higher than with normal ATLs (p = 0.015). ALT and AST levels in males with MetS were higher than without MetS (p = 0.022 and p = 0.025, respectively) (Table 4).

Table 2.

The p values of comparisons between normal and elevated aminotransferase levels in all participants, male and female.

  All Participants  Male  Female 
No. (normal/elevated*949/132  444/91  505/41 
Age (year)  NS  NS  NS 
Physical activity  NS  NS  NS 
Height (cm)  0.038  NS  NS 
Weight (kg)  < 0.0001  0.004  0.002 
Waist circumference (cm)  < 0.0001  0.001  0.003 
Hip circumference (cm)  NS  0.015  NS 
Waist-to-hip ratio  < 0.0001  0.009  0.023 
Systolic blood pressure (mmHg)  NS  NS  NS 
Diastolic blood pressure (mmHg)  0.050  NS  0.045 
Body mass index (kg/m20.012  NS  <0.0001 
Blood glucose level (mg/dL)  NS  NS  NS 
Total cholesterol level (mg/dL)  < 0.0001  < 0.0001  0.002 
LDL cholesterol level (mg/dL)  0.004  0.024  0.005 
HDL cholesterol level (mg/dL)  0.040  NS  0.010 
Triglyceride level (mg/dL)  < 0.0001  < 0.0001  0.003 

*

Except the individuals with hepatitis

NS: Not significant;

Table 3.

The distributions of the criteria for MetS in individuals with elevated aminotransferase levels without hepatitis (132 persons).

  n (%) 
No risk  12 (9.1%) 
One risk  29 (22.0%) 
Two risk  32 (24.2%) 
MetS (≥Three risk)  59 (44.7%) 

MetS: Metabolic syndrome.

Table 4.

The comparisons of participants with elevated aminotransferase levels according to metabolic syndrome.

  All participants (n=132)Male (n=91)Female (n = 41)
  MetS (+) (n = 59)  MetS (-) (n = 73)  p-value  MetS (+) (n = 31)  MetS (-) (n = 60)  p-value  MetS (+) (n = 28)  MetS (-) (n = 13)  p-value 
Age, year  46.1 ± 15.9  38.6 ± 14.7  0.006  43.6 ± 17.0  39.5 ± 15.3  NS  48.8 ± 14.4  34.6 ± 9.1  0.002 
ALT  71.4 ± 28.3  64.6 ± 22.8  NS  76.8 ± 29.3  63.4 ± 15.8  0.022  65.5 ± 26.4  70.3 ± 43.0  NS 
AST  42.8 ± 15.4  35.6 ± 9.8  0.003  40.1 ± 13.3  34.0 ± 8.8  0.025  45.7 ± 17.3  43.2 ± 11.2  NS 

MetS: Metabolic syndrome. NS: Non significant.

Alcohol intake (p = 0.015), smokers (p < 0.0001) and drug using (p = 0.002) were higher in individuals with elevated ATLs.

The participants with MetS had more elevated ALT levels compared with the participants without MetS, but this difference was not significant (71.4 ± 28.3 U/L vs. 64.6 ± 22.8 U/L, p = 0.136).

When the males with elevated ATLs were evaluated, the ALT levels of the persons who have no risk of MetS (p = 0.007) and the persons who have one risk of MetS (p = 0.001) were lower than the persons with MetS (Figure 1, Table 5). However, there were no statistical significant in females with elevated ATLs for risk factors of MetS.

Figure 1.

ALT levels according to risk factors for metabolic syndrome in men with elevated aminotransferase levels.

(0.05MB).
Table 5.

The distributions of risk factors for metabolic syndrome in men with elevated aminotransferase levels.

    Metabolic Risk Factors 
  No risk  One risk  Two risk  > Three risk (MetS)* 
No.  10  23  27  31 
Mean ALT  59.8 ± 12.8  59.6 ± 12.6  68.0 ± 18.3  76.8 ± 29.3 

*

Metabolic syndrome.

The ALT levels of the participants with elevated aminotransferase in living rural and urban areas are 67.2 ± 26.7 and 68.1 ± 24.4, respectively (p = 0.837). Similarly, we didn’t find statistically significant differences in males and females according to residence (p = 0.775 and p = 0.576, respectively).

Discussion

The prevalence of elevated serum ATLs (ALT and / or ASTA was found 13.3% in our asymptomatic general population. Moreover, about 117 of our participants (120 persons) had elevated ALT levels. Ioannou et al found that the prevalence of elevated ALT, AST, or either ALT or AST were 8.9%, 4.9%, and 9.8%, respectively.9 Jamali et al in general population of Iran10 and Liu et al in Taiwan11 declared that the elevated ALT levels were 7.9% and 7.2%, respectively. Papatheodoridis et al found that elevated liver enzymes are present in approximately 15% of Greek blood donors.12 Our study showed that the prevalence of elevated ATLs was relatively higher in our population. Although the prevalence of alcohol consumption is very low, this result may relate to the increased ratio of smoking, hepatitis, obesity, and MetS.

It was demonstrated that elevated aminotransfe-rase levels have a relationship with features of the MetS.13-15 The most common causes associated with elevated ATLs were elevated BMI, fatty liver, and MetS in our general population. Interestingly, the participants with the MetS had more elevated ALT levels than those without the MetS. However, this difference was not significant. The prevalence of MetS in individuals with elevated ATLs was higher in females than males. Moreover, elevated ATLs have been associated with at least one etiologic factor such as MetS, fatty liver, drug using, hepatitis, etc. in all participants. However, we found that ALT levels have a relationship with risk of MetS only in males with elevated ATLs.

The waist circumference is an important marker of central obesity.16 When we were evaluate hip-waist circumference, waist-to-hip ratio and BMI bet-ween the participants with normal and elevated ATLs, there were a statistical significant for waist-to-hip ratio as waist circumference. This finding shows the importance of waist-to-hip ratio. De Lé-dinghen, et al. found that liver fibrosis is statistically associated with tobacco use, elevated BMI and diabetes in 272 asymptomatic patients with unexplained chronically elevated ALT levels.17 Elevated ATLs were more common among males than fema-les.12,17,18 Similarly, our study confirmed that the ratio of elevated ATLs was higher in males and in smokers.

Fatty liver was found in 64% of 149 asymptomatic participants with elevated serum aminotransfera-ses.19 Daniel et al demonstrated that a lot of participants with chronic elevated transaminase have liver steatosis.20 Liver biopsy is often recommended in patients with elevated serum aminotrans-ferases in order to determine the causes. It was a deficiency of our study that we did not perform liver biopsy.

Conclusion

Elevated aminotransferase levels are common and MetS is an important cause of elevated ATLs in Northern Turkey. The ALT levels increase with the number of risk of the MetS in males. Moreover, the results of our study indicate that the most common causes associated with elevated ATLs may be prevented with lifestyle modification such as dietary habits, physical activity in our population.

Abbreviations

  • ATLs: Elevated aminotransferase levels.

  • MetS: Metabolic syndrome.

  • ALT: Alanine aminotransferase.

  • AST: Aspartate aminotransferase.

Financial Support

This project was funded by The Society of Science Research Projects in Gaziosmanpasa University, Project number: 2005/26.

Reference
[1.]
Pratt D.S., Kaplan M.M..
Evaluation of abnormal liver-enzyme results in asymptomatic patients.
N Engl J Med, 342 (2000), pp. 1266-1271
[2.]
Piton A., Poynard T., Imbert-Bismut F., Khalil L., Delattre J., Pelissier E., et al.
Factors associated with serum alanine transaminase activity in healthy subjects: consequences for the definition of normal values, for selection of blood donors, and for patients with chronic hepatitis C. MULTI-VIRC Group.
Hepatology, 27 (1998), pp. 1213-1219
[3.]
Ruhl C.E., Everhart J.E..
Determinants of the association of overweight with elevated serum alanine aminotransferase activity in the United States.
Gastroenterology, 124 (2003), pp. 71-79
[4.]
Meltzer A.A., Everhart J.E..
Association between diabetes and elevated serum alanine aminotransferase activity among Mexican Americans.
Am J Epidemiol, 146 (1997), pp. 565-571
[5.]
Ioannou G.N., Weiss N.S., Boyko E.J., Kahn S.E., Lee S.P..
Contribution of metabolic factors to alanine aminotransferase activity in persons with other causes of liver disease.
Gastroenterology, 128 (2005), pp. 627-635
[6.]
Yildirim B., Barut S., Bulut Y., Yenisehirli G., Ozdemir M., Cetin I., et al.
Seroprevalence of Hepatitis B and C Viruses in The Province of Tokat in Black Sea Region of Turkey: A Population-Based Study.
Turk J Gastroenterol, 20 (2009), pp. 27-30
[7.]
Kisacik B., Yildirim B., Tasliyurt T., Ozyurt H., Ozyurt B., Yuce S., et al.
Increased frequency of familial Mediterranean fever in northern Turkey: a population-based study.
Rheumatol Int, 29 (2009), pp. 1307-1309
[8.]
Saverymuttu S.H., Joseph A.E., Maxwell J.D..
Ultrasound scanning in the detection of hepatic fibrosis and steatosis.
Br J Med, 292 (1986), pp. 13-15
[9.]
Ioannou G.N., Boyko E.J., Lee S.P..
The prevalence and predictors of elevated serum aminotransferase activity in the United States in 1999-2002.
Am J Gastroenterol, 101 (2006), pp. 76-82
[10.]
Jamali R., Khonsari M., Merat S., Khoshnia M., Jafari E., Bahram Kalhori A., et al.
Persistent alanine aminotransferase elevation among the general Iranian population: prevalence and causes.
World J Gastroenterol, 14 (2008), pp. 2867-2871
[11.]
Liu C.M., Tung T.H., Liu J.H., Chen V.T., Lin C.H., Hsu C.T., Chou P..
A community-based epidemiological study of elevated serum alanine aminotransferase levels in Kinmen, Taiwan.
World J Gastroenterol, 11 (2005), pp. 1616-1622
[12.]
Papatheodoridis G.V., Goulis J., Christodoulou D., Manolakopoulos S., Raptopoulou M., Andrioti E., et al.
High prevalence of elevated liver enzymes in blood donors: associations with male gender and central adiposity.
Eur J Gastroenterol Hepatol, 19 (2007), pp. 281-287
[13.]
Nannipieri M., Gonzales C., Baldi S., Posadas R., Williams K., Haffner S.M., et al.
Liver enzymes, the metabolic syndrome, and incident diabetes: the Mexico City diabetes study.
Diabetes Care, 28 (2005), pp. 1757-1762
[14.]
Nakanishi N., Suzuki K., Tatara K..
Serum gamma-glutamyltransferase and risk of metabolic syndrome and type 2 diabetes in middle-aged Japanese men.
Diabetes Care, 27 (2004), pp. 1427-1432
[15.]
Hanley A.J., Williams K., Festa A., Wagenknecht L.E., D’Agostino R.B. Jr, Haffner S.M..
Liver markers and development of the metabolic syndrome: the insulin resistance atherosclerosis study.
Diabetes, 54 (2005), pp. 3140-3147
[16.]
Grundy S.M., Brewer H.B. Jr, Cleeman J.I., Smith S.C. Jr, Lenfant C..
American Heart Association; National Heart, Lung, and Blood Institute. Definition of metabolic syndrome: Report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition.
Circulation, 109 (2004), pp. 433-438
[17.]
De Lédinghen V., Ratziu V., Causse X., Le Bail B., Capron D., Renou C., et al.
Diagnostic and predictive factors of significant liver fibrosis and minimal lesions in patients with persistent unexplained elevated transaminases. A prospective multicenter study.
J Hepatol, 45 (2006), pp. 592-599
[18.]
Kundrotas L.W., Clement D.J..
Serum alanine aminotransferase (ALT) elevation in asymptomatic US Air Force basic trainee blood donors.
Dig Dis Sci, 38 (1993), pp. 2145-2150
[19.]
Hultcrantz R., Glaumann H., Lindberg G., Nilsson L.H..
Liver investigation in 149 asymptomatic patients with moderately elevated activities of serum aminotransferases.
Scand J Gastroenterol, 21 (1986), pp. 109-113
[20.]
Daniel S., Ben-Menachem T., Vasudevan G., Ma C.K., Blumenkehl M..
Prospective evaluation of unexplained chronic liver transaminase abnormalities in asymptomatic and symptomatic patients.
Am J Gastroenterol, 94 (1999), pp. 3010-3014

Except the individuals with hepatitis

Metabolic syndrome.

Copyright © 2010. Fundación Clínica Médica Sur, A.C.
Descargar PDF
Opciones de artículo
es en pt

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?

Você é um profissional de saúde habilitado a prescrever ou dispensar medicamentos

Quizás le interese:
10.1016/j.aohep.2024.101519
No mostrar más